Obesity drug supply-demand imbalance is working in Novo Nordisk’s favor: Mizuho’s Jared Holz

Obesity drug supply-demand imbalance is working in Novo Nordisk’s favor: Mizuho’s Jared Holz

February 1, 2024

Jared Holz, Mizuho Securities, joins ‘Fast Money’ to talk demand in the obesity drug space and who is benefiting from the supply-demand imbalance.

Share This

Latest Mizuho News

Payment stocks down due policy uncertainty, says Mizuho’s Dan Dolev

Payment stocks down due policy uncertainty, says Mizuho’s Dan Dolev

January 13, 2026

Why Dutch Bros is a top stock pick for 2026, while Starbucks lags

Why Dutch Bros is a top stock pick for 2026, while Starbucks lags

December 23, 2025

Keeping current furniture tariff rates benefits home furnishings sector: Mizuho’s Bellinger

Keeping current furniture tariff rates benefits home furnishings sector: Mizuho’s Bellinger

January 2, 2026

Mizuho news from around the globe

Mizuho Global News